Nonstatins for LDL-C lowering: An expansion whose time has come

Area of Science:

• Cardiology
• Lipidology
• Pharmacotherapy

Background:

• The 2026 ACC/AHA Dyslipidemia Guideline reinstates LDL-C and non-HDL-C treatment goals.
• Statin monotherapy is often insufficient for achieving lipid goals, particularly in high-risk or statin-intolerant patients.

Purpose of the Study:

• To review the expanded role of nonstatin therapies in lipid management.
• To discuss new outcomes data supporting lower LDL-C targets.
• To explore the future of LDL-C-lowering therapies.

Main Methods:

• Review of current guidelines and outcomes data.
• Analysis of the role of existing nonstatin agents.
• Exploration of emerging lipid-lowering therapies.

Main Results:

• Nonstatin therapies are now integral to evidence-based care for dyslipidemia.
• New data support the "lower is better" principle for LDL-C reduction.
• Next-generation therapies promise personalized care and improved adherence.

Conclusions:

• Combination lipid-lowering therapy is essential for achieving optimal LDL-C levels.
• Achieving and sustaining target lipid levels significantly reduces atherosclerotic cardiovascular disease risk.
• The evolving landscape of lipid-lowering therapies offers new strategies for individualized patient care.